#United States #San Francisco #J.P. Morgan #CAR therapy #CREATE Medicines

CREATE Medicines to Showcase Innovative CAR Therapy at J.P. Morgan Healthcare Conference

CREATE Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

Cambridge, Mass., Jan. 8, 2026 – CREATE Medicines, a pioneering clinical-stage biotechnology company specializing in in vivo CAR therapy, has officially announced its participation in the prestigious 44th Annual J.P. Morgan Healthcare Conference. The event is set to take place in San Francisco on January 15, 2026, at 9:30 a.m. PT.

The CEO and co-founder, Dr. Daniel Getts, expressed his enthusiasm about the upcoming presentation, stating, "We are excited to present at the J.P. Morgan Healthcare Conference and to share updates from the largest clinical dataset of in vivo CAR therapies. In addition, we will present new proof-of-concept data demonstrating best-in-class B cell depletion with in vivo CAR-T in non-human primates leveraging CREATE's proprietary de-risked platform."

This event marks a pivotal moment for CREATE Medicines, as it will unveil the latest developments in their groundbreaking research. The company is known for its innovative approach to CAR therapy, which transforms immune cells directly within patients’ bodies. The results presented will focus on the efficacy of their proprietary mRNA-LNP platform, which enables scalable, repeat-dose immunotherapies, thus opening new doors in the fight against cancer and autoimmune diseases.

Presentation Highlights

The CREATE Medicines presentation at the conference will cover several significant aspects:

1. Clinical Data: The company will provide comprehensive insights from its extensive clinical dataset related to in vivo CAR therapies, offering a glimpse into the reliability and success rates of their treatments.
2. B Cell Depletion Data: Notably, CREATE will showcase new evidence regarding the efficiency of its in vivo CAR-T therapy in depleting B cells in non-human primate models. This data underscores the therapeutic's potential effectiveness and safety.
3. Industry Impact: These findings are expected to play a crucial role in shaping future immunotherapy strategies, particularly in oncology and autoimmune conditions. They highlight the company's commitment to advancing healthcare and improving patient outcomes.

About CREATE Medicines

CREATE Medicines is at the forefront of the biotechnology field, focusing on in vivo CAR therapy. Their mRNA-LNP platform is a revolutionary method for directly programming immune cells within the body, allowing for the provision of effective treatments that are off-the-shelf, scalable, and suitable for repeat dosing. With human validation already achieved, CREATE is now advancing a pipeline of in vivo CAR therapies aimed at transforming treatment outcomes for cancer patients and those suffering from autoimmune diseases.

For further details about their innovative approaches and ongoing developments, interested parties are encouraged to visit their official website. Additionally, CREATE Medicines actively engages with the community on platforms such as LinkedIn and X (formerly Twitter).

Final Remarks

As the J.P. Morgan Healthcare Conference approaches, the anticipation surrounding CREATE Medicines' presentation continues to grow. Healthcare professionals and investors alike will be eager to learn about the advancements in CAR therapies and the potential they hold for the future of treatment. With their commitment to innovation and patient care, CREATE Medicines is set to make a significant impact in the healthcare sector.

For media inquiries, please contact: